Therapeutic Strategies in the Management of COVID-19
Since December 2019, SARS-CoV-2 (COVID-19), novel corona virus has caused pandemic globally, with rise in the number of cases and death of the patients. Vast majority of the countries that are dealing with rise in the active cases and death of patients suffering from novel corona viruses COVID-19 ar...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-02-01
|
| Series: | Frontiers in Molecular Biosciences |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2020.636738/full |
| _version_ | 1818677115537588224 |
|---|---|
| author | Rajashri R. Naik Ashok K. Shakya |
| author_facet | Rajashri R. Naik Ashok K. Shakya |
| author_sort | Rajashri R. Naik |
| collection | DOAJ |
| description | Since December 2019, SARS-CoV-2 (COVID-19), novel corona virus has caused pandemic globally, with rise in the number of cases and death of the patients. Vast majority of the countries that are dealing with rise in the active cases and death of patients suffering from novel corona viruses COVID-19 are trying to content the virus by isolating the patients and treating them with the approved antiviral that have been previously used in treating SARS, MERS, and drugs that are used to treat other viral infections. Some of these are under clinical trials. At present there are no therapeutically effective antiviral present and there are no vaccines or drugs available that are clinically approved for treating the corona virus. The current strategy is to re-purpose the available drugs or antiviral that can minimise or reduce the burden of the health care emergencies. In this article the reuse of antiviral, US-FDA approved drugs, plant based therapeutic, anti-malarial, anti-parasitic, anti–HIV drugs and the traditional medicines that are being currently used in treating the symptoms of COVID–19 patients is discussed emphasis is also given on the treatment using monoclonal antibodies. The present article provides the therapeutic strategies that will qualify as one of the best available treatment for the better management of the COVID–19 patients in order to achieve medical benefits. |
| first_indexed | 2024-12-17T08:54:14Z |
| format | Article |
| id | doaj.art-bbbc2ab09a434fbd89f17f9769e38b17 |
| institution | Directory Open Access Journal |
| issn | 2296-889X |
| language | English |
| last_indexed | 2024-12-17T08:54:14Z |
| publishDate | 2021-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Biosciences |
| spelling | doaj.art-bbbc2ab09a434fbd89f17f9769e38b172022-12-21T21:56:00ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2021-02-01710.3389/fmolb.2020.636738636738Therapeutic Strategies in the Management of COVID-19Rajashri R. Naik0Ashok K. Shakya1Department of Biopharmaceutics and Clinical Pharmacy, Pharmacological and Diagnostic Research Center, Al-Ahliyya Amman University, Amman, JordanDepartment of Pharmaceutical Sciences, Pharmacological and Diagnostic Research Center, Al-Ahliyya Amman University, Amman, JordanSince December 2019, SARS-CoV-2 (COVID-19), novel corona virus has caused pandemic globally, with rise in the number of cases and death of the patients. Vast majority of the countries that are dealing with rise in the active cases and death of patients suffering from novel corona viruses COVID-19 are trying to content the virus by isolating the patients and treating them with the approved antiviral that have been previously used in treating SARS, MERS, and drugs that are used to treat other viral infections. Some of these are under clinical trials. At present there are no therapeutically effective antiviral present and there are no vaccines or drugs available that are clinically approved for treating the corona virus. The current strategy is to re-purpose the available drugs or antiviral that can minimise or reduce the burden of the health care emergencies. In this article the reuse of antiviral, US-FDA approved drugs, plant based therapeutic, anti-malarial, anti-parasitic, anti–HIV drugs and the traditional medicines that are being currently used in treating the symptoms of COVID–19 patients is discussed emphasis is also given on the treatment using monoclonal antibodies. The present article provides the therapeutic strategies that will qualify as one of the best available treatment for the better management of the COVID–19 patients in order to achieve medical benefits.https://www.frontiersin.org/articles/10.3389/fmolb.2020.636738/fullCOVID-19hydroxychlorquinechloroquinelopinavir/ritonavirremdesivirfavipiravir |
| spellingShingle | Rajashri R. Naik Ashok K. Shakya Therapeutic Strategies in the Management of COVID-19 Frontiers in Molecular Biosciences COVID-19 hydroxychlorquine chloroquine lopinavir/ritonavir remdesivir favipiravir |
| title | Therapeutic Strategies in the Management of COVID-19 |
| title_full | Therapeutic Strategies in the Management of COVID-19 |
| title_fullStr | Therapeutic Strategies in the Management of COVID-19 |
| title_full_unstemmed | Therapeutic Strategies in the Management of COVID-19 |
| title_short | Therapeutic Strategies in the Management of COVID-19 |
| title_sort | therapeutic strategies in the management of covid 19 |
| topic | COVID-19 hydroxychlorquine chloroquine lopinavir/ritonavir remdesivir favipiravir |
| url | https://www.frontiersin.org/articles/10.3389/fmolb.2020.636738/full |
| work_keys_str_mv | AT rajashrirnaik therapeuticstrategiesinthemanagementofcovid19 AT ashokkshakya therapeuticstrategiesinthemanagementofcovid19 |